Función del profesional en enfermería en la atención del acoso escolar en niños, niñas y adolescentes

Actualmente se ha incrementado y visualizado el fenómeno del acoso escolar o bullying(por su traducción al inglés); sin embargo, llama la atención que esta práctica ha  existido durante mucho tiempo, pero es hasta ahora donde se evidencian las consecuencias que genera en los niños, niñas y adolescentes que, según diversos estudios, puede generar suicidios en esta población. Diversas profesiones han profundizado en el tema; a pesar de ello, no se ha visto avance en el manejo y prevención del acoso y se ha incrementado el número de casos que llegan a instituciones de salud relacionados con los daños físicos y psicológicos que se ocasionan en el niño víctima de acoso escolar. Es un reto para enfermería poder abordar esta situación y plantear posibles estrategias de intervención para su manejo y prevención, no solo en la víctima y victimario sino también en la familia, escuelas e instituciones de salud en los diferentes niveles de atención, ya que cuenta con las herramientas para diseñar intervenciones en el manejo de la comunidad y del paciente institucionalizado. &nbsp

Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy

BACKGROUND: The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of cases. Formin homology 2 domain containing 3 (FHOD3) may have a role in the pathogenesis of cardiac hypertrophy but has not been implicated in hypertrophic cardiomyopathy. OBJECTIVES: This study sought to investigate the relation between FHOD3 mutations and the development of hypertrophic cardiomyopathy. METHODS: FHOD3 was sequenced by massive parallel sequencing in 3,189 hypertrophic cardiomyopathy unrelated probands and 2,777 patients with no evidence of cardiomyopathy (disease control subjects). The authors evaluated protein-altering candidate variants in FHOD3 for cosegregation, clinical characteristics, and outcomes. RESULTS: The authors identified 94 candidate variants in 132 probands. The variants' frequencies were significantly higher in patients with hypertrophic cardiomyopathy (74 of 3,189 [2.32%]) than in disease control subjects (18 of 2,777 [0.65%]; p < 0.001) or in the gnomAD database (1,049 of 138,606 [0.76%]; p < 0.001). FHOD3 mutations cosegregated with hypertrophic cardiomyopathy in 17 families, with a combined logarithm of the odds score of 7.92, indicative of very strong segregation. One-half of the disease-causing variants were clustered in a small conserved coiled-coil domain (amino acids 622 to 655); odds ratio for hypertrophic cardiomyopathy was 21.8 versus disease control subjects (95% confidence interval: 1.3 to 37.9; p < 0.001) and 14.1 against gnomAD (95% confidence interval: 6.9 to 28.7; p < 0.001). Hypertrophic cardiomyopathy patients carrying (likely) pathogenic mutations in FHOD3 (n = 70) were diagnosed after age 30 years (mean 46.1 ± 18.7 years), and two-thirds (66%) were males. Of the patients, 82% had asymmetric septal hypertrophy (mean 18.8 ± 5 mm); left ventricular ejection fraction <50% was present in 14% and hypertrabeculation in 16%. Events were rare before age 30 years, with an annual cardiovascular death incidence of 1% during follow-up. CONCLUSIONS: FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2% of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Estas son algunas de las habilidades blandas demandadas en Colombia

Este producto forma parte de una serie de infografías de divulgación científica que buscan reseñar algunas de las investigaciones más importantes en las que ha tenido participación la Universidad EAFIT, publicadas en las revistas especializadas más prestigiosas del mund

Role of the nursing professional in the attention of bullying in children and adolescents

Actualmente se ha incrementado y visualizado el fenómeno del acoso escolar o bullying(por su traducción al inglés); sin embargo, llama la atención que esta práctica ha&nbsp; existido durante mucho tiempo, pero es hasta ahora donde se evidencian las consecuencias que genera en los niños, niñas y adolescentes que, según diversos estudios, puede generar suicidios en esta población. Diversas profesiones han profundizado en el tema; a pesar de ello, no se ha visto avance en el manejo y prevención del acoso y se ha incrementado el número de casos que llegan a instituciones de salud relacionados con los daños físicos y psicológicos que se ocasionan en el niño víctima de acoso escolar. Es un reto para enfermería poder abordar esta situación y plantear posibles estrategias de intervención para su manejo y prevención, no solo en la víctima y victimario sino también en la familia, escuelas e instituciones de salud en los diferentes niveles de atención, ya que cuenta con las herramientas para diseñar intervenciones en el manejo de la comunidad y del paciente institucionalizado. &nbsp;Currently the phenomenon of bullying has increased and visualized, however, it is striking that this practice has existed for a long time, but it is up until now where the consequences that it generates in the children and adolescents are shown, where, according to various studies, can generate suicides in this population. Various professions have deepened the issue; despite this, there has not been progress in the management and prevention of harassment and it has increased the number of cases that reach health institutions related to physical and psychological damage that are caused in the child victim of bullying. It is a challenge for nursing to tackle this situation and propose possible intervention strategies for its management and prevention, not only in the victim and victimizer, but also in the family, schools, and health institutions in the different levels of care, since it has the tools to design interventions in the management of the community and the institutionalized patien

Seven disagreements about cooperative learning

Accounting education faces significant challenges in many countries as it seeks to meet the demand of the profession in the twenty-first century. One of those requirements is that young professionals have teamwork skills. Therefore, many universities include group work activities in their curriculum. In the daily experience, however, students and instructors sometimes hold negative feelings about cooperative learning. Therefore, this article addresses seven disagreements on cooperative learning, frequently mentioned by students and instructors. In particular, (1) group work is only invented to reduce grading time; (2) putting students into a group turns them automatically into a team; (3) teamwork certainly has a positive effect on student satisfaction; (4) free riding, social loafing, or a reduction in effort are simply inevitable; (5) peer assessment solves all problems; (6) guiding teamwork is a piece of cake; and (7) teamwork reduces the individual student's workload. The paper gives a voice to these issues and provides suggestions for improvement in relation to any or all aspects of cooperative learning in accounting education. A theoretical framework of cooperative learning is presented and ideas to overcome many (or all of the) problems on group work are provided

Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy.

The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of cases. Formin homology 2 domain containing 3 (FHOD3) may have a role in the pathogenesis of cardiac hypertrophy but has not been implicated in hypertrophic cardiomyopathy. This study sought to investigate the relation between FHOD3 mutations and the development of hypertrophic cardiomyopathy. FHOD3 was sequenced by massive parallel sequencing in 3,189 hypertrophic cardiomyopathy unrelated probands and 2,777 patients with no evidence of cardiomyopathy (disease control subjects). The authors evaluated protein-altering candidate variants in FHOD3 for cosegregation, clinical characteristics, and outcomes. The authors identified 94 candidate variants in 132 probands. The variants' frequencies were significantly higher in patients with hypertrophic cardiomyopathy (74 of 3,189 [2.32%]) than in disease control subjects (18 of 2,777 [0.65%]; p  FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2% of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels